Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
CAMBRIDGE, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera's eProtein Discovery System with Cytiva's Biacore™ surface plasmon resonance (SPR) technology.
Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera's eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva's Biacore SPR system.
Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: 'Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery's ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery's capability to streamline protein production workflows with Cytiva's Biacore protein characterization systems open a whole new avenue for accelerating drug development.'
Anna Moberg, Senior Manager and Project Manager, Cytiva, added: 'The ability of Nuclera's eProtein Discovery to accelerate protein production and purification complements Cytiva's Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.'
For more information about Nuclera's eProtein Discovery System, please visit:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Corrao Group Launches MyFirst TPM™
Affordable, Scalable, and Faster-To-Deploy Trade Promotion Management (TPM) Solution SAN DIEGO, June 3, 2025 /PRNewswire/ -- Corrao Group, a global leader in Salesforce Consumer Goods Cloud implementations, today announced the official launch of MyFirst TPM™. MyFirst TPM™ is an entry-point implementation exclusively leveraging Salesforce TPM to enable fast-growing CPG brands that need structure, speed, and scalability—without a 12-month build or a massive price tag. Trade Promotion Management is a critical capability for consumer goods companies, allowing them to plan, execute, and measure promotions that drive volume and influence shopper behavior. According to research, trade spend often accounts for up to 20% of annual revenue, so the ability to track ROI and optimize performance is essential. However, traditional TPM system implementations have been costly, complex, and time-consuming, making them out of reach for many fast-growing brands. MyFirst TPM™ was designed to solve this by offering a streamlined, scalable, and more affordable path to TPM success on Salesforce. "Emerging consumer goods companies need fast, effective ways to deploy trade promotion management solutions so they can effectively manage trade programs that capture increasingly price-sensitive consumers," said Achyut Jajoo, SVP and GM, Manufacturing, Automotive, & Consumer Goods at Salesforce. "Corrao Group's MyFirst TPM™ is a fast, value-driven, and proven solution for deploying Salesforce's Trade Promotion Management technology tailored to each brand's needs. It harnesses the AI, data and industry-specific innovation from Consumer Goods Cloud to give brands the ability to build effective trade plans, optimize spend, and fuel more profitable growth." Why MyFirst TPM™ Matters For years, consumer goods and retail customers have encountered a similar challenge: they want a TPM tool but quickly turn away from traditional deployments' price, timeline, and complexity. MyFirst TPM™ aims to solve this by offering: Affordable Entry Point: Core Salesforce TPM capabilities at a fraction of the cost. Accelerated Deployment: Delivered in just five months. Right-Sized Functionality: Standardized features designed to meet common CPG planning needs. Future-Ready Architecture: Built to scale as customers grow into more advanced trade promotion strategies. AI-Enabled Insights: Post-promotion analysis and insights, helping brands make smarter, faster decisions. "Corrao Group is pleased to announce the official launch of MyFirst TPM™, the inaugural solution in our new MyFirst Family of offerings. MyFirst TPM™ empowers emerging consumer goods brands with a rapid, cost-effective, and scalable path to adopt Salesforce's comprehensive trade promotion management application. This solution is built to meet companies at their current stage and seamlessly support their growth into the future. With MyFirst TPM™, we are opening a new chapter in how we help fast-growing brands accelerate their digital transformation and achieve operational excellence," said Jack Corrao II, Managing Partner of Corrao Group. About Corrao Group Since 2008, Corrao Group has been a trusted global Salesforce partner, helping B2B organizations across retail, consumer goods, manufacturing, and healthcare drive digital transformation. Our expertise spans Salesforce Consumer Goods Cloud for Sales & Service, Retail Execution (REx), Customer Planning & Forecasting (CPF), Trade Promotion Management (TPM), Agentforce, and Data Cloud. With seamless integration and a deep understanding of industry challenges, we translate complex business processes into scalable, high-performing Salesforce solutions. As power users and implementation experts, we optimize operations, enhance decision-making, and accelerate growth—ensuring your business stays ahead in a competitive market. Please visit to learn more. Additional Resources Follow Corrao Groupon LinkedIn and X Follow Salesforce on LinkedIn and X Contact: Jack Corrao III, jcorraoiii@ View original content: SOURCE Corrao Group
Yahoo
3 hours ago
- Yahoo
Richmond American Set to Build New Jacksonville Community
Laurelton will showcase beautiful homes with open layouts and designer details JACKSONVILLE, Fla., June 3, 2025 /PRNewswire/ -- Richmond American Homes of Florida, LP, a subsidiary of M.D.C. Holdings, Inc., is pleased to announce that it recently purchased and closed on 151 future homesites in Jacksonville. The land is set to become Laurelton, an exciting new master-planned community in Clay County. This notable neighborhood will offer nine inspired floor plans from the builder's popular Seasons™ Collection ( designed to optimize living space and make homeownership more accessible. All homes will showcase professionally curated fixtures and finishes ( "We're excited to welcome Richmond American Homes of Florida to Laurelton," said Noah Breakstone, CEO of BTI Partners, the master developer behind the community. "Our approach has always centered on partnering with respected builders to bring thoughtfully planned neighborhoods to life. Laurelton is more than just new homes - it's about creating spaces where people can connect with nature, their neighbors, and a lifestyle that reflects how they truly want to live." More about Laurelton: New single- and two-story homes from the $400s 9 thoughtfully designed Seasons™ Collection floor plans Generous homesites Designer-curated fixtures and finishes Near St. John's River Close proximity to shopping, dining and prominent employment hubs Community schools, golf course, clubhouse, trails, grocery store and more Call 561.409.1040 or visit for more information. About M.D.C. Holdings, Inc. M.D.C. Holdings, Inc. was founded in 1972. MDC's homebuilding subsidiaries, which operate under the name Richmond American Homes, have helped more than 250,000 homebuyers achieve the American Dream since 1977. One of the largest homebuilders in the nation, MDC is committed to quality and value that is reflected in each home its subsidiaries build. The Richmond American companies have operations in Alabama, Arizona, California, Colorado, Florida, Idaho, Maryland, Nevada, New Mexico, Oregon, Tennessee, Texas, Utah, Virginia and Washington. Mortgage lending, insurance and title services are offered by the following MDC subsidiaries, respectively: HomeAmerican Mortgage Corporation, American Home Insurance Agency, Inc. and American Home Title and Escrow Company. For more information, visit About BTI Partners BTI Partners is one of Florida's leading real estate and land developers. The company is reshaping cities across Florida by master-planning vibrant mixed-use communities, building luxury residential projects in strategic locations, re-activating marinas, and revitalizing neighborhoods with highly amenitized commercial and residential developments in urban areas. Core values of integrity, passion, excellence, selflessness and purpose are central to the company's ethos. Its successful track record has established BTI Partners as an industry leader in creating urban enclaves that attract and sustain local business and family life. By seamlessly integrating residential, commercial, retail, hospitality, entertainment, education, and recreational uses, BTI Partners designs highly desirable 'live, work, play' communities to meet the needs of today and tomorrow. A forward-looking company, BTI Partners remains ever mindful of evolving trends and continuously seeks opportunities to develop transformational and inspirational mixed-use projects through-out the sunbelt states. View original content to download multimedia: SOURCE M.D.C. Holdings, Inc. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Establishment Labs to Present at Jefferies Global Healthcare Conference
NEW YORK, June 03, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at Archived versions of the webcasts will be available on the same website following the completion of the events. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Sign in to access your portfolio
